February 13, 2026
FOCUS on Drug Repurposing. A study just published in Neuron suggests the HIV drug Maraviroc (a CCR5 antagonist) may be useful for the treatment of glioblastoma […]
December 30, 2025
FOCUS on Drug Failures. On December 22nd AstraZeneca reported on the LATIFY Phase III trial of ATR inhibitor ceralasertib (AZD6738) in combination with Imfinzi (Durvalumab), which […]
December 19, 2025
FOCUS on Drug Approvals. On December 17th the FDA granted regular approval to PARP inhibitor drug Rubraca (Rucaparib, pharmaand GmbH), for treatment of adults with a […]
December 5, 2025
FOCUS on Drug Approvals. The FDA has approved the first cancer drug based on discoveries from the Broad Institute of MIT and Harvard. Sevabertinib (BAY-2927088) was […]
November 24, 2025
FOCUS on New Drug Approvals. On November 13th the FDA announced approval of Ziftomenib (Komzifti, Kura Oncology), a menin inhibitor, for the treatment of adults with […]
November 14, 2025
FOCUS on Drug Repurposing. Moxidectin is an anthelmintic drug approved by the FDA in 2018 for onchocerciasis (river-blindness). It is a derivative of milbemycin, a structurally […]
November 12, 2025
FOCUS on Drug Repurposing. Moxidectin is an anthelmintic drug approved by the FDA in 2018 for onchocerciasis (river-blindness). It is a derivative of milbemycin, a structurally […]
November 6, 2025
FOCUS on New Drug Approvals. The FDA just announced approval of Revumenib, a first-in-class oral menin inhibitor, for the treatment of adults and children with relapsed […]
October 29, 2025
FOCUS on SIRT6. Sirtuin 6 (SIRT6) is an NAD-dependent histone deacetylase shown to function as a tumor suppressor in several cancer types. However, the therapeutic potential […]